The vice president of Republic, Rachel Peñaassured today that the contracts for the acquisition of vaccines with the pharmaceutical Pfizer and AstraZeneca They are in legal hands.
“That is in legal hands and really what we have is the responsibility to defend those contracts, and to defend every penny that is invested, not only in vaccines, in anything that has been invested for the country”, he indicated. Peña.
“That contract is there and we are going to defend it”said the vice president who also heads the Health Cabinet.
You can read: Dominican Government will “discard” expired vaccines; most are AstraZeneca
Contract
The government Dominican signed on October 30, 2020 a contract with the company British biopharmaceutical company AstraZeneca for the acquisition of 10 million doses of its vaccine against COVID-19.
President Louis Abinader and the vice president Rachel Penareported that the contract was an advance purchase agreement for the acquisition of the antiviral.
For these purposes, the government invested $40 million corresponding to four dollars by vaccine. It should be noted that the first payment was eight million dollars provided by the private sector.
expired vaccines
The Ministry of Public Health reported that if they could not deliver to other countries the vaccines close to expiration these would be discarded or incinerated.
“When a vaccine can no longer be used, it is discarded, incinerated. There is an amount that expires in March,” said the deputy minister. Eladio Perez Antonio.
In that same order, the governing body of health in Dominican Republic assured that the expired vaccines So far they are from AstraZeneca.
“They were basically AstraZeneca”, Pérez Antonio said while also pointing out that “the expiration date were variants”.
You can read: WHO warns pandemic is not over, nor is its damage to the economy
AstraZeneca
AstraZeneca It’s a company biopharmaceutical global scientific company that focuses on the discovery, development and commercialization of prescription drugs, mainly for the treatment of diseases in three therapeutic areas: Oncology, Cardiovascular, Renal and Metabolic and Respiratory and Immunology.
The AZD1222 It was the first vaccine against COVID-19 in initiating the process of continuous review of the European Medicines Agency (EMA). Other regulatory agencies, including Canada, Japan, Brazil, Mexico, Chile, Australia, South Korea and Switzerland they have also initiated review protocols for the vaccine.
–
